Ascendis Pharma Doubles Footprint in Princeton

On Oct 16, 2025

Today, Ascendis Pharma held a ribbon-cutting ceremony to celebrate the opening of its new and expanded office in Princeton, located at 212 Carnegie Center Boulevard. With this location, the company strengthens Ascendis’ presence across North America and supports its commitment to serve the unmet needs of patients with rare endocrinology conditions. 

The number of employees of the Ascendis U.S. business has more than doubled from 2024 to 2025. This growth includes a shift from just under 50 employees located in the Princeton office to plans for well more than 100 employees (including currently open positions). With the new office location, Ascendis’ Princeton footprint also almost doubled, expanding from 11,805 square feet to 22,040 square feet with the potential to grow further.

At today’s event, in acknowledgement of its commitment to developing and delivering therapies for rare conditions, Pamela Gavin, CEO, National Organization for Rare Disorders (NORD), presented Jay Donovan Wu, executive vice president and president, US Market Ascendis Pharma, with a NORD Rare Impact Award for Industry Innovation in recognition of the company’s work developing and launching the first and only treatment for hypoparathyroidism in adults. Patty Keating and Michele Rayes, representatives of non-profit HypoPARAthyroidism Association, Inc., shared patient perspectives on living with that disease.

Local guests on hand for the ribbon cutting included NJ Assemblyman Roy Freiman (D-16), Devin Mulroy, chief of staff for Assemblyman Roy Freiman, and Rachel Cohen, senior business development officer, Choose NJ, as well as Debbie Hart, president and CEO, BioNJ, and Dr. John Coelho, Senior Advisor, life sciences with the New Jersey Economic Development Authority.

Hart spoke about the vital role Ascendis plays in New Jersey’s life sciences community — creating jobs, cultivating talent and infusing our innovation ecosystem with fresh energy and scientific excellence, while Dr. Coelho highlighted NJ’s role as an ideal location for life sciences innovation. 

To access more business news, visit NJB News Now.

Related Articles: